Baskozos, Georgios
Themistocleous, Andreas C.
Hebert, Harry L.
Pascal, Mathilde M. V.
John, Jishi
Callaghan, Brian C.
Laycock, Helen
Granovsky, Yelena
Crombez, Geert
Yarnitsky, David
Rice, Andrew S. C.
Smith, Blair H.
Bennett, David L. H.
Funding for this research was provided by:
Diabetes UK (19/0005984, 19/0005984)
Medical Research Council (MR/W002388/1, MR/W002388/1, MR/W002388/1, MR/W002388/1, MR/W002388/1, MR/W002388/1, MR/W002388/1, MR/W002388/1)
Versus Arthritis (MR/W002388/1, MR/W002388/1, MR/W002388/1, MR/W002388/1, MR/W002388/1, MR/W002388/1, MR/W002388/1, MR/W002388/1)
H2020 European Research Council (633491, 633491, 633491, 633491, 633491, 633491, 633491, 633491, 633491, 633491)
Article History
Received: 12 November 2021
Accepted: 24 May 2022
First Online: 29 May 2022
Declarations
:
: All data from active human participants used and analysed in this study has been previously collected.All methods were carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by the respective institutions and licensing committees. Informed consent was obtained from all subjects and/or their legal guardian(s). Ethics consent for all studies has been previously approved by their regional ethics committees as required by national law. The “Pain In Neuropathy Study (PiNS)”, University of Oxford UK, has been approved by the National Research Ethics Service—West London REC 3 (No.: 10/H07056/35). “DOLORisk Dundee: Development of a Risk Model for (severe) Neuropathic Pain”, University of Dundee UK, has been approved by the Health Research Authority—NRES Committee Yorkshire & The Humber—South Yorkshire (REC: 15/YH/0285, IRAS project ID: 181986). “DOLORisk: Understanding risk factors and determinants for neuropathic pain”, Imperial College London has been approved by London—Bromley Research Ethics Committee (REC: 16/LO/1470, IRAS project ID: 209707). “Understanding Risk Factors and Determinants for Neuropathic Pain”, Technion—Israel Institute of Technology, has been approved by the Helsinki Committee of Rambam Health Care Campus (Reference: 0052–15-RNB, NCT: NCT02402361).
: Not available.
: Dr. Callaghan consults for Dynamed and performs medical legal consultations including the Vaccine Injury Compensation Program. He also receives research support from the American Academy of Neurology. Andrew SC Rice reports conflicts of interest occurring in last 24 months: ASCR undertakes consultancy and advisory board work for Imperial College Consultants- ASCR undertakes consultancy and advisory board work for Imperial College Consultants- in the last 36 months this has included remunerated work for: Abide, Confo, Vertex, Pharmanovo, Lateral, Novartis, Mundipharma, Orion, Shanghai SIMR BiotechAsahi Kasei, Toray & Theranexis. ASCR was the owner of share options in Spinifex Pharmaceuticals from which personal benefit accrued upon the acquisition of Spinifex by Novartis in July 2015. The final payment was made in 2019. ASCR is named as an inventor on patents: Rice A.S.C., Vandevoorde S. and Lambert D.M Methods using N-(2-propenyl)hexadecanamide and related amides to relieve pain. WO 2005/079771. Okuse K. et al. Methods of treating pain by inhibition of vgf activity EP13702262.0/ WO2013 110945. Councillor International Association Study of Pain. National Institute for Health Research (NIHR)—Chair of the Trial Steering Committee (TSC) for the OPTION-DM trial. Advisor British National Formulary. Member Joint Committee on Vaccine and Immunisation- varicella sub-committee. Analgesic Clinical Trial Translation: Innovations, Opportunities, and Networks (ACTTION) steering committee member. Non Freezing Cold Injury Independent Senior Advisory Committee (NISAC): Member. Medicines and Healthcare products Regulatory Agency (MHRA), Commission on Human Medicines—Neurology, Pain & Psychiatry Expert Advisory Group. All other authors report no competing interests.